Graves眼病患者甲状腺功能亢进症治疗中消融性与保守性方案的比较:一项回顾性队列研究
本回顾性队列研究纳入49例Graves甲状腺功能亢进症合并中重度活动性Graves眼病患者,24例接受放射性碘治疗、25例接受甲巯咪唑治疗,所有患者均静脉给予甲泼尼龙。第24周放射性碘组眼病总体缓解率高于甲巯咪唑组(54.1% vs 16%;放射性碘组感染更常见。
要点
- 第48和72周两组眼病总体缓解率无差异,甲巯咪唑组缓解率随时间增加。
核心结论
- 放射性碘治疗似乎与Graves眼病对静脉糖皮质激素更早出现应答相关。
- 长期来看,保守性方案似乎也有效。
- 当患者同时接受糖皮质激素治疗时,放射性碘治疗似乎相对安全。
- 作者认为需要随机临床试验来证实这些发现。
研究设计与样本
- 回顾性队列研究,纳入49例连续患者,均为Graves甲状腺功能亢进症合并中重度活动性Graves眼病(按欧洲Graves眼病专家组指南定义)。
- 24例接受放射性碘治疗,25例接受甲巯咪唑治疗,所有患者均接受静脉甲泼尼龙治疗。
- 随访访视在第24、48和72周进行,主要终点为第24周Graves眼病总体结局。
主要发现
- 第48和72周甲巯咪唑组缓解率增加,两组间无差异。
- 第24周仅放射性碘组1例(4%)和甲巯咪唑组3例(12%)出现Graves眼病加重。
关键数值与推荐
- 缓解定义为以下眼征中至少两项变化:临床活动度评分降低≥1分;眼球突出减少≥2 mm;睑裂宽度减少≥2 mm;眼球运动度增加≥8度。
- 放射性碘组随访时长72周(四分位距66-72),甲巯咪唑组随访时长72周(四分位距48-72)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要随机临床试验来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Treatment for Graves' hyperthyroidism (GH) in patients with Graves' orbitopathy (GO) remains a topic of debate. This study aimed to investigate the outcome of GO following glucocorticoids, depending on the chosen thyroid treatment. Methods: This retrospective cohort study included 49 consecutive patients with GH and moderate-to-severe, active GO, as defined by the European Group on Graves' Orbitopathy guidelines. Twenty-four patients were treated with radioactive iodine (RAI) and 25 with methimazole (MMI). All patients were administered intravenous methylprednisolone. Follow-up visits occurred at weeks 24, 48, and 72. The primary endpoint was the overall outcome of GO at week 24. Response was defined as a change in at least two of the following eye features: reduction ≥1 point in clinical activity score; proptosis reduction ≥2 mm; eyelid aperture reduction ≥2 mm; increase in eye ductions ≥8 degrees. Results: Follow-up duration was 72 weeks for both groups (interquartile range 66-72 for RAI and 48-72 for MMI). The proportion of responders for week 24 overall GO outcome was greater in RAI (54.1% vs. 16%; odds ratio [OR] 6.2 [confidence interval (CI): 1.6-23.6], p = 0.0075), but it increased in MMI at weeks 48 and 72, with no differences between groups. There was a trend indicating a better response in RAI regarding individual eye features. Improvement in GO-specific quality of life questionnaire at week 24 was trendily more pronounced in RAI (responders 50% vs. 28% in MMI; OR = 2.5 [CI: 0.7-8.4], p = 0.11), although results were similar in both groups at later time points. At week 24, only one patient (4%) in RAI and three (12%) in MMI experienced worsening of GO. Fifty-nine adverse events were recorded among 36 patients, with no differences between groups, except for infections, which were more frequent in RAI (53.8% vs. 15.3% in MMI; OR = 6.41 [CI: 1.7-23.9], p = 0.0056). Conclusions: RAI appears to be associated with an earlier response of GO to intravenous glucocorticoids. In the long term, a conservative approach also seems to be effective. RAI appears to be relatively safe when patients are concurrently treated with glucocorticoids. However, randomized clinical trials are necessary to confirm these findings.
引用
- Cosentino G, Lanzolla G, Comi S, et al. Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves' Orbitopathy: A Retrospective Cohort Study. Thyroid. 2025. PMID: 39909466. doi:10.1089/thy.2024.0633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。